GlassScriptPhysician profile
Brittany D Ramirez
NPI 1184929234
$2,901.98
in general payments reported to CMS, 2019-2025
19 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $333 · 2023: $267 · 2024: $391 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197 · Education: $39.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.94 |
| Education | $39.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,611.80 | 2021-2025 | |
| Janssen Biotech, INC. | $313.92 | 2022-2025 | Tremfya |
| Pfizer INC. | $141.55 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $122.72 | 2021 | |
| Gilead Sciences, INC. | $97.21 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.83 | 2024-2025 | Entyvio |
| Ardelyx, INC. | $86.71 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $83.96 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $58.45 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.05 | 2025 | Trulance, Relistor |
| Intercept Pharmaceuticals, INC. | $51.88 | 2021-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $42.37 | 2025 | Rezdiffra |
| Qol Medical, LLC | $32.27 | 2022-2025 | Sucraid |
| Merck Sharp & Dohme LLC | $26.09 | 2022 | |
| Genzyme Corporation | $24.39 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $22.17 | 2022 | |
| Lilly USA, LLC | $15.48 | 2024 | Omvoh |
| Novo Nordisk INC | $15.07 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.